Clinical Trial

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

Study acronym: ZEBRHA 2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors or with hemophilia A of any severity (severe, moderate, and mild) with FVIII inhibitors.
Protocol Amendment History 5 changes
notable Trial sites expanded: 12 -> 30 locations 2026-08-07
notable Trial sites expanded: 8 -> 12 locations 2026-07-08
notable Trial sites expanded: 3 -> 6 locations 2026-05-08
critical Recruitment opened 2026-04-08
notable Trial sites expanded: 0 -> 3 locations 2026-04-08
Trial Details
NCT Number NCT07416604
Lead Sponsor Hoffmann-La Roche
Collaborators: Chugai Pharmaceutical
Conditions Hemophilia A
Enrollment 360 participants
Start Date 2026-04-27
Primary Completion 2028-02-29 (estimated)
Study Completion 2032-01-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-06